CA2871535A1 - Biomarkers for the treatment of hepatocellular carcinoma - Google Patents
Biomarkers for the treatment of hepatocellular carcinoma Download PDFInfo
- Publication number
- CA2871535A1 CA2871535A1 CA2871535A CA2871535A CA2871535A1 CA 2871535 A1 CA2871535 A1 CA 2871535A1 CA 2871535 A CA2871535 A CA 2871535A CA 2871535 A CA2871535 A CA 2871535A CA 2871535 A1 CA2871535 A1 CA 2871535A1
- Authority
- CA
- Canada
- Prior art keywords
- biomarker
- tcf
- subject
- level
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5067—Liver cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586672P | 2012-01-13 | 2012-01-13 | |
| US61/586,672 | 2012-01-13 | ||
| PCT/US2013/021197 WO2013106686A1 (en) | 2012-01-13 | 2013-01-11 | Biomarkers for the treatment of hepatocellular carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2871535A1 true CA2871535A1 (en) | 2013-07-18 |
Family
ID=47604231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2871535A Withdrawn CA2871535A1 (en) | 2012-01-13 | 2013-01-11 | Biomarkers for the treatment of hepatocellular carcinoma |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8901110B2 (https=) |
| EP (1) | EP2802877A1 (https=) |
| JP (1) | JP2015504677A (https=) |
| CN (1) | CN104737021A (https=) |
| AU (1) | AU2013202104B2 (https=) |
| CA (1) | CA2871535A1 (https=) |
| MX (1) | MX2014008388A (https=) |
| WO (1) | WO2013106686A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2428513T3 (en) | 2006-09-26 | 2017-08-21 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
| JP5959543B2 (ja) | 2011-03-11 | 2016-08-02 | セルジーン コーポレイション | ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンの固体形態、並びにそれらの医薬組成物及び使用 |
| ES2814952T3 (es) | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
| IL278381B2 (en) * | 2013-12-06 | 2024-08-01 | Celgene Corp | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer |
| CN103645259B (zh) * | 2013-12-12 | 2015-03-11 | 深圳海王药业有限公司 | 一种同时测定泊马度胺及其有关物质的方法 |
| WO2016060702A1 (en) * | 2014-10-13 | 2016-04-21 | Celgene Corporaton | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| CN108048568B (zh) * | 2017-12-25 | 2021-02-02 | 贵州省人民医院 | Plcd4基因作为胃腺癌转移诊断标志物的用途 |
| CN109266747B (zh) * | 2018-09-21 | 2021-07-27 | 中国医学科学院北京协和医院 | 与i型神经纤维瘤合并脊柱畸形病相关gpr56及其应用 |
| EP3863615A4 (en) * | 2018-10-14 | 2022-08-03 | Lantern Pharma Inc. | METHODS OF TREATMENT OF CANCERS WITH SOLID TUMORS USING ILLUDINS AND BIOMARKERS |
| US20220289821A1 (en) * | 2018-11-29 | 2022-09-15 | Trillium Therapeutics Inc | Biomarkers for cd47 blockade therapy |
| CN116064810A (zh) * | 2022-11-10 | 2023-05-05 | 杭州医学院 | CD24作为Hippo通路失活亚型肝细胞癌生物标志物的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1166651C (zh) * | 2001-06-08 | 2004-09-15 | 北京大学药学院 | 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物 |
| US7803783B2 (en) * | 2002-12-06 | 2010-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Use of WNT inhibitors to augment therapeutic index of chemotherapy |
| WO2011109237A2 (en) * | 2010-03-02 | 2011-09-09 | Emory University | Uses of noscapine and derivatives in subjects diagnosed with fap |
-
2013
- 2013-01-11 EP EP13701319.9A patent/EP2802877A1/en not_active Withdrawn
- 2013-01-11 CA CA2871535A patent/CA2871535A1/en not_active Withdrawn
- 2013-01-11 JP JP2014552323A patent/JP2015504677A/ja active Pending
- 2013-01-11 AU AU2013202104A patent/AU2013202104B2/en not_active Ceased
- 2013-01-11 MX MX2014008388A patent/MX2014008388A/es unknown
- 2013-01-11 CN CN201380014334.8A patent/CN104737021A/zh active Pending
- 2013-01-11 US US13/740,012 patent/US8901110B2/en active Active
- 2013-01-11 WO PCT/US2013/021197 patent/WO2013106686A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013202104A1 (en) | 2013-08-01 |
| CN104737021A (zh) | 2015-06-24 |
| MX2014008388A (es) | 2014-11-14 |
| US20130183675A1 (en) | 2013-07-18 |
| JP2015504677A (ja) | 2015-02-16 |
| EP2802877A1 (en) | 2014-11-19 |
| WO2013106686A1 (en) | 2013-07-18 |
| US8901110B2 (en) | 2014-12-02 |
| AU2013202104B2 (en) | 2015-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8901110B2 (en) | Use of biomarkers in methods for the treatment of hepatocellular carcinoma | |
| JP7142612B2 (ja) | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 | |
| US20170242014A1 (en) | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies | |
| US20180231561A1 (en) | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies | |
| Werner et al. | Expression of epithelial mesenchymal transition and cancer stem cell markers in circulating tumor cells | |
| JP2020523022A (ja) | 免疫療法に反応する肝細胞癌のクラスの検出および治療方法 | |
| CN103026229B (zh) | 用于治疗银屑病的生物标志物 | |
| CN101990577A (zh) | 鉴定肺病药物开发的新途径 | |
| Xie et al. | Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma | |
| US20160153998A1 (en) | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma | |
| JP2025111438A (ja) | イルジンおよびバイオマーカーを使用した固形腫瘍癌の治療方法 | |
| US20120329061A1 (en) | Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of cancer patients | |
| Jiang et al. | TFE3 is a diagnostic marker for solid pseudopapillary neoplasms of the pancreas | |
| JP7177096B2 (ja) | 乳癌を検出する方法 | |
| Vanhove et al. | Biopsy-derived intestinal epithelial cell cultures for pathway-based stratification of patients with inflammatory bowel disease | |
| AU2017299513A1 (en) | Biomarkers for detection and treatment of mast cell activity-associated disorders | |
| CN117752795B (zh) | T5224在抑制肝癌侵袭、转移中的应用 | |
| Pan et al. | Elevated expression of yes‑associated protein is associated with the malignant status and prognosis of laryngeal squamous cell carcinoma | |
| Lammert et al. | PAX8‐positive conventional urothelial carcinomas of the urinary bladder and their distinct molecular profiles–A clinicopathologic study of 101 consecutive cases with next‐generation sequencing in 20 cases | |
| US20110111396A1 (en) | Biomarkers for monitoring the treatment by quinazolinone compounds | |
| JP5140808B2 (ja) | 消化管間質腫瘍（ｇｉｓｔ）を患う患者の予後を予測するために使用する腫瘍マーカー及びキット並びにフェチンの使用方法 | |
| Rodrigues | Cancer stem cells in liver cancer | |
| Foglia | STUDY ON THE ROLE OF HYPOXIA-INDUCIBLE FACTOR 2α AND SERPINB3 IN RELATION TO LIVER CARCINOGENESIS | |
| Corrò | Dissecting tumor heterogeneity and cancer stem cell properties in clear cell renal cell carcinoma | |
| Zhong et al. | Molecular profiling plasma extracellular vesicle unveils features associated with breast cancer aggression, metastasis and invasion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AZWI | Withdrawn application |
Effective date: 20170824 |